Research ExplorerPublicationsAdjuvant therapy in node-positive vulvar cancer

Adjuvant therapy in node-positive vulvar cancer

Standard

Adjuvant therapy in node-positive vulvar cancer. / Mahner, Sven; Trillsch, Fabian; Kock, Lilli; Rohsbach, Donata; Petersen, Cordula; Krüll, Andreas; Harter, Philipp; Jänicke, Fritz; Woelber, Linn.

In: EXPERT REV ANTICANC, Vol. 13, No. 7, 01.07.2013, p. 839-44.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Mahner, S, Trillsch, F, Kock, L, Rohsbach, D, Petersen, C, Krüll, A, Harter, P, Jänicke, F & Woelber, L 2013, 'Adjuvant therapy in node-positive vulvar cancer', EXPERT REV ANTICANC, vol. 13, no. 7, pp. 839-44. https://doi.org/10.1586/14737140.2013.811063

APA

Mahner, S., Trillsch, F., Kock, L., Rohsbach, D., Petersen, C., Krüll, A., Harter, P., Jänicke, F., & Woelber, L. (2013). Adjuvant therapy in node-positive vulvar cancer. EXPERT REV ANTICANC, 13(7), 839-44. https://doi.org/10.1586/14737140.2013.811063

Vancouver

Mahner S, Trillsch F, Kock L, Rohsbach D, Petersen C, Krüll A et al. Adjuvant therapy in node-positive vulvar cancer. EXPERT REV ANTICANC. 2013 Jul 1;13(7):839-44. https://doi.org/10.1586/14737140.2013.811063

Bibtex

@article{fa0f6a2988df48419b3a0adc9fda77b5,
title = "Adjuvant therapy in node-positive vulvar cancer",
abstract = "Due to an increasing incidence with concurrently decreasing age at onset, vulvar cancer represents a current challenge for gynecologic oncologists. Positive lymph nodes of the groins have been proven to be the most important prognostic factor for affected patients, significantly impairing overall survival. Distinct criteria for indication of adjuvant therapy following primary tumor resection and groin surgery are still under debate. At present, only patients with two or more positive lymph nodes are treated with adjuvant radiotherapy despite growing evidence that patients with only one nodal macrometastasis already have a significantly worse outcome and might benefit from adjuvant treatment. This review discusses existing evidence focusing on different therapeutic approaches and their potential indication in vulvar cancer. Based on the available data the need for future trials is being elaborated.",
keywords = "Age of Onset, Chemoradiotherapy, Adjuvant, Chemotherapy, Adjuvant, Female, Humans, Lymph Nodes, Lymphatic Metastasis, Prognosis, Radiotherapy, Adjuvant, Survival Rate, Vulvar Neoplasms",
author = "Sven Mahner and Fabian Trillsch and Lilli Kock and Donata Rohsbach and Cordula Petersen and Andreas Kr{\"u}ll and Philipp Harter and Fritz J{\"a}nicke and Linn Woelber",
year = "2013",
month = jul,
day = "1",
doi = "10.1586/14737140.2013.811063",
language = "English",
volume = "13",
pages = "839--44",
journal = "EXPERT REV ANTICANC",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "7",

}

RIS

TY - JOUR

T1 - Adjuvant therapy in node-positive vulvar cancer

AU - Mahner, Sven

AU - Trillsch, Fabian

AU - Kock, Lilli

AU - Rohsbach, Donata

AU - Petersen, Cordula

AU - Krüll, Andreas

AU - Harter, Philipp

AU - Jänicke, Fritz

AU - Woelber, Linn

PY - 2013/7/1

Y1 - 2013/7/1

N2 - Due to an increasing incidence with concurrently decreasing age at onset, vulvar cancer represents a current challenge for gynecologic oncologists. Positive lymph nodes of the groins have been proven to be the most important prognostic factor for affected patients, significantly impairing overall survival. Distinct criteria for indication of adjuvant therapy following primary tumor resection and groin surgery are still under debate. At present, only patients with two or more positive lymph nodes are treated with adjuvant radiotherapy despite growing evidence that patients with only one nodal macrometastasis already have a significantly worse outcome and might benefit from adjuvant treatment. This review discusses existing evidence focusing on different therapeutic approaches and their potential indication in vulvar cancer. Based on the available data the need for future trials is being elaborated.

AB - Due to an increasing incidence with concurrently decreasing age at onset, vulvar cancer represents a current challenge for gynecologic oncologists. Positive lymph nodes of the groins have been proven to be the most important prognostic factor for affected patients, significantly impairing overall survival. Distinct criteria for indication of adjuvant therapy following primary tumor resection and groin surgery are still under debate. At present, only patients with two or more positive lymph nodes are treated with adjuvant radiotherapy despite growing evidence that patients with only one nodal macrometastasis already have a significantly worse outcome and might benefit from adjuvant treatment. This review discusses existing evidence focusing on different therapeutic approaches and their potential indication in vulvar cancer. Based on the available data the need for future trials is being elaborated.

KW - Age of Onset

KW - Chemoradiotherapy, Adjuvant

KW - Chemotherapy, Adjuvant

KW - Female

KW - Humans

KW - Lymph Nodes

KW - Lymphatic Metastasis

KW - Prognosis

KW - Radiotherapy, Adjuvant

KW - Survival Rate

KW - Vulvar Neoplasms

U2 - 10.1586/14737140.2013.811063

DO - 10.1586/14737140.2013.811063

M3 - SCORING: Journal article

C2 - 23875662

VL - 13

SP - 839

EP - 844

JO - EXPERT REV ANTICANC

JF - EXPERT REV ANTICANC

SN - 1473-7140

IS - 7

ER -